Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,801–2,900 of 4,628
Thrainsson, L., Halldórsson, A. B., Ingason, A. B., Ísaksson, H. J., Gudmundsson, G., & Guðbjartsson, T. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1107 · Cited by 7
Huang, C., Sun, Y., Ma, C., Jiao, P., Wu, Q., Tian, W., Yu, H., & Tong, H. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02508-1 · Cited by 9
Cassel, S. E., Huntington, B. M., Chen, W., Lei, P., Andreadis, S. T., & Kloxin, A. M. (2024) · APL Bioengineering · doi:10.1063/5.0166152 · Cited by 6
Assessment of Imatinib Anti-Remodeling Activity on a Human Precision Cut Lung Slices Model
Bozzinì, S., Bozza, E., Bagnera, C., Morbini, P., Lettieri, S., Zoppa, M. D., Melloni, G., Saracino, L., Belliato, M., & Meloni, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158186 · Cited by 5
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2024) · Respiration · doi:10.1159/000540856 · Cited by 13
Self-citationPatient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Viswanathan, V. K., Ghoshal, A. G., Mohan, A., Patil, K., Bhargave, C., CHOUDHARI, S. Y., & Mehta, S. C. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00271-1 · Cited by 9
Kulkarni, T., Flaherty, K. R., Gupta, S., Tu, Y.-H., & Case, A. H. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202404-430rl · Cited by 7
Self-citationBalakrishnan, B., AZAR, J. J., Farha, S., Goyanes, A. M., Lane, J. E., Paul, D., Highland, K. B., Wang, Y., Wang, X., & Tonelli, A. R. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107835 · Cited by 6
Matsuda, S., Kotani, T., Okazaki, A., Nishioka, D., Masuda, Y., Shiomi, M., Watanabe, R., Taniguchi, T., Manabe, A., Kadoba, K., et al. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03453-z · Cited by 6
Xie, Y., Zhang, P., Ren, J., Chen, T., Wang, J., & Li, J. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12659 · Cited by 6
Wang, F., Jin, L., Wang, X., Cui, B., Yang, Y., Duggan, L., Sterman, A. S., Lloyd, S. M., Hazelwood, L. A., Chaudhary, N., et al. (2025) · Proteomes · doi:10.3390/proteomes13010003 · Cited by 8
Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis
Liu, S., Popowski, K. D., Eckhardt, C. M., Zhang, W., Li, J., Jing, Y., Silkstone, D., Belcher, E., Cislo, M., Hu, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202405434 · Cited by 15
Platenburg, M. G. J. P., Nakshbandi, G., Moor, C. C., van Batenburg, A. A., Mostard, R. L. M., Voortman, M., Moonen, L. A. A., Hekelaar, N., Overbeek, M. J., Bogaarts, B. A. H. A., et al. (2025) · Respirology · doi:10.1111/resp.70030 · Cited by 8
“Studies in IPF have demonstrated that around 10% of patients have disease progression in the first year after treatment [24, 25].”
Mao, S., Yu, N. H., Wang, W., Mao, Y., Du, Y., Zhao, Q., Gu, X., & Kang, J. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10031-9 · Cited by 8
Algal bioactives: Unlocking future frontiers in respiratory therapeutics
Pakan, P. D., Siu, A. C. W., Lee, H., Singh, M., Rubis, G. D., Yeung, S., Kulkarni, M. P., Goh, B. H., Hsu, A., Chellappan, D. K., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106778 · Cited by 8
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
Anderson, A., Shifren, A., & Nathan, S. D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1187129 · Cited by 5
Acupuncture for idiopathic pulmonary fibrosis
Xie, Y., Wang, J., Li, G., et al. (2017) · Medicine · doi:10.1097/md.0000000000009114 · Cited by 5
Systemic sclerosis phase III clinical trials: Hope on the horizon?
Aringer, M., & Denton, C. P. (2018) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198318775353 · Cited by 6
Was der Rheumatologe vom Pneumologen lernen kann
Leuschner, G., & Neurohr, C. (2018) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-018-0507-5 · Cited by 6
Pharmacological treatment of pulmonary fibrosis
Choi, W.-I. (2020) · Journal of Korean Medical Association · doi:10.5124/jkma.2020.63.1.47 · Cited by 5
Wang, H., Shah, C. A., Hu, L., Huang, W., Platanias, L. C., & Eklund, E. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013206 · Cited by 5
“To test this, we treated primary recipients of MLL1-ELL–transduced bone marrow with nintedanib, an inhibitor of TRIAD1-substrate RTKs, including FGF-R, PDGF-R, and VEGF-R (30).”
BackgroundMethodInfluentialEarly referral to palliative care in IPF – pitfalls and opportunities in clinical trials
Kalluri, M., Bendstrup, E. M., Lindell, K. O., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01418-9 · Cited by 5
Infections and systemic sclerosis: an emerging challenge
Correa, J. E. B., la Hoz, A. D., López, M. J., Garzón, J., Allanore, Y., & Quintana‐López, G. (2020) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.12.004 · Cited by 8
Legué, S., Marchand-Adam, S., Plantier, L., Bayeh, B. A., Morel, H., Mangiapan, G., & Flament, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-039078 · Cited by 5
Davis, R., Dixon, C., Millar, A., Maskell, N. A., & Barratt, S. L. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01520-8 · Cited by 7
Xiao-ling, Z., Yuan, S., Zheng, X., Wang, X., & Zhang, J. (2022) · Inflammation · doi:10.1007/s10753-022-01653-w · Cited by 6
Takahashi, S., Endo, M., Fukuda, Y., Ogawa, K., Nakamura, M., Okada, K., Kawahara, M., Akahane, K., Nagatomo, T., Onaga, R., et al. (2022) · Case Reports in Oncology · doi:10.1159/000526077 · Cited by 5
Zheng, Q., Cox, I. A., de Graaff, B., Campbell, J. A., Corte, T. J., Glaspole, I., Navaratnam, V. V., Hopkins, P. M.-A., Zappala, C. J., Ahmad, H., et al. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03331-8 · Cited by 5
Antifibrotic in interstitial lung diseases: When, where, and how long?
Rai, D. K., & Tripathi, S. (2022) · Lung India · doi:10.4103/lungindia.lungindia_283_22 · Cited by 5
“the rate of decline in the FVC after 1 year of treatment with nintedanib and pirfenidone, respectively.[7,8] A”
BackgroundIdiopathic pulmonary fibrosis and intestinal disorders: An observational study
Caramaschi, S., Bertani, A., Cerri, S., Antonio, C., Andrea, A.-S., Manco, G., Salviato, T., & Bonetti, L. R. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.152072 · Cited by 6
Cigliano, A., Strain, A. J., & Cadamuro, M. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2023.09 · Cited by 5
Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Morros, M., Ramón, A., & Armengol, S. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01278-3 · Cited by 7
Drug like HSP27 cross linkers with chromenone structure ameliorates pulmonary fibrosis
Yoo, Y. J., Jeon, S., Jin, H. K., Won, H. Y., Jeong, M. G., Cho, Y., Hwang, E. S., Na, Y., Cho, J., & Lee, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1203033 · Cited by 5
“Furthermore, both therapies commonly exhibit side effects, primarily affecting the gastrointestinal system (Richeldi et al., 2014).”
BackgroundProtein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases
Yu, H. K. Y., Zaveri, S., Sattar, Z., Schaible, M., Gandara, B. P., Uddin, A., McGarvey, L. R., Ohlmeyer, M. H. J., & Geraghty, P. M. (2023) · Medicina · doi:10.3390/medicina59091552 · Cited by 5
“The frequency of IPF is increasing [10], with the estimated occurrence rates of IPF increasing from approximately 3 to 9 cases per 100,000 individuals annually in Europe and North America between 1998 and 2012 [11].”
BackgroundKaunisto, J., Salomaa, E.-R. M., Koivisto, M. A., & Myllärniemi, M. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02630-1 · Cited by 10
Wu, J., Liu, X., Zhang, J., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106930 · Cited by 5
Wang, Z., Liu, M., Ai, Y., Zheng, S., Chen, Y., Du, H., Yuan, S., Guo, X., Yuan, Y., Li, G., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102268 · Cited by 5
Diagnosis of interstitial lung diseases: from Averill A. Liebow to artificial intelligence
Yi, E. S., Wawryko, P., & Ryu, J. H. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.17 · Cited by 7
Ukita, J., Nishikiori, H., Hirota, K., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078841 · Cited by 5
Hamada, A., Yasaka, K., Hatano, S., Kurokawa, M., Inui, S., Kubo, T., Watanabe, Y., & Abe, O. (2024) · Canadian Association of Radiologists Journal · doi:10.1177/08465371241228468 · Cited by 5
Takuma, S., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Mori, K., Shimizu, M., Inoue, Y., Yasui, H., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107542 · Cited by 4
Self-citationDuch, P., Díaz‐Valdivia, N., Gabasa, M., Ikemori, R., Arshakyan, M., Fernández‐Nogueira, P., Llorente, A., Teixidó, C., Ramírez, J., Pereda, J., et al. (2024) · Cancer Science · doi:10.1111/cas.16141 · Cited by 6
Zamparelli, S. S., Lombardi, C., Candia, C., Iovine, P. R., Rea, G., Vitacca, M., Ambrosino, P., Bocchino, M., & Maniscalco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072026 · Cited by 14
The multifaceted role of macrophage mitophagy in SiO2‐induced pulmonary fibrosis: A brief review
Zhou, Y., Li, S., Du, S., Zhao, J., Cai, Y., & Zhang, Z. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4612 · Cited by 8
Gao, Z.-Y., Xu, M.-Z., Liu, C., Gong, K., Yu, X., Lu, K., Zhu, J., Guan, H., & Zhu, Q. (2024) · Pharmaceuticals · doi:10.3390/ph17050584 · Cited by 5
Samarelli, A. V., Tonelli, R., Raineri, G., Mastrolia, I., Costantini, M., Fabbiani, L., Catani, V., Petrachi, T., Bruzzi, G., Andrisani, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12061321 · Cited by 6
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
Freeberg, M. A. T., Thatcher, T. H., Camus, S., Huang, L., Atkinson, J. M., Narrow, W. C., Haak, J., Dylag, A. M., Cowart, L. A., Johnson, T. S., et al. (2024) · Physiological Reports · doi:10.14814/phy2.16012 · Cited by 7
Xing, X., Zhao, C., Cai, S., Wang, J., Zhang, J., Sun, F., Huang, M., & Zhang, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379480 · Cited by 6
Ferroptosis: A New Strategy for the Treatment of Fibrotic Diseases
Pei, Z., Fan, J., Tang, M., & Li, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400383 · Cited by 7
Macrophages in Lung Repair and Fibrosis
de Sá, Y. A. P. J., Creyns, B., Hogaboam, C. M., Parks, W. C., & Hohmann, M. S. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-65944-7_10 · Cited by 7
Amubieya, O., Todd, J. L., Neely, M. L., Kaner, R. J., Lasky, J. A., Namen, A. M., Heßlinger, C., Palmer, S. M., WEIGT, S. S., & Belperio, J. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312044 · Cited by 8
Pan, C., Wei, H., Chen, B., Wu, L., Song, J., Zhang, Q., Wu, X., Liang, G., Chen, W., Wang, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05895-0 · Cited by 7
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments
Duong‐Quy, S., Hai, C. N., Huynh-Anh, T., & Nguyen‐Nhu, V. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2438322 · Cited by 5
Examining Cough’s Role and Relief Strategies in Interstitial Lung Disease
Lim, C. Y., Khan, S. W., ALSIBAI, T., & Sathiyamoorthy, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14010291 · Cited by 6
“Nintedanib is a tyrosine kinase inhibitor targeting the vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor pathways and is approved for treating IPF and slowing the disease progression [60].”
Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis
Xiao, X., Huang, G., Yu, X., & Tan, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s488226 · Cited by 6
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.004 · Cited by 10
Xu, C., Xu, Z., & Ren, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1555442 · Cited by 6
“In two Phase III clinical trials (INPULSIS-1 and INPULSIS-2), it has been demonstrated that NTB treatment significantly slows the decline of FVC in patients with IPF (47).”
InfluentialIdiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Tourin, O., Swigris, J. J., & Olson, A. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_2 · Cited by 5
Velez, M. I., & Nambiar, A. M. (2015) · Respirology · doi:10.1111/resp.12487 · Cited by 5
Adegunsoye, A., Levy, M., & Oyenuga, O. A. (2015) · BioMed Research International · doi:10.1155/2015/929170 · Cited by 5
Varone, F., Mastrobattista, A., Franchi, P., Viglietta, L., Poletti, V. E., Tomassetti, S., Dubini, A., Tagliaboschi, L., Calandriello, L., Farchione, A., et al. (2016) · The Clinical Respiratory Journal · doi:10.1111/crj.12515 · Cited by 5
Sakhri, L., Saint‐Raymond, C., Quétant, S., Pison, C. M., Lagrange, E., Roy, R. H., Janssens, J.-P., Maindet, C., Garrouste-Orgeas, M., Lévy-Soussan, M., et al. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.06.005 · Cited by 3
New Treatments for Idiopathic Pulmonary Fibrosis
Meyer, K. C., & Modi, D. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000166 · Cited by 5
Pirfenidone and mortality in idiopathic pulmonary fibrosis
Spagnolo, P. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30416-7 · Cited by 7
Nerves, Cough, and Idiopathic Pulmonary Fibrosis
Harrison, N. K., & Pynn, M. (2015) · EMJ Respiratory · doi:10.33590/emjrespir/10312904 · Cited by 5
Cleveland, Z. I., Zhou, Y., Akinyi, T. G., Dunn, R. S., Davidson, C. R., Guo, J., Woods, J. C., & Hardie, W. D. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00458.2016 · Cited by 6
Inchingolo, R., Condoluci, C., Smargiassi, A., Mastrobattista, A., Boccabella, C., Comes, A., Golfi, N., & Richeldi, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1383382 · Cited by 7
Self-citationCell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation
Podolsky, M. J., Gupta, D., Ha, A., Ta, R., Khalifeh‐Soltani, A., McKleroy, W., Datta, R., Sheppard, D., & Atabai, K. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00144.2018 · Cited by 5
“Pulmonary fibrosis is a particularly vexing clinical problem with few effective therapies that slow the progression of fibrosis and none that reverse fibrosis once it has been established (31, 55, 56).”
BackgroundWells, A. U. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30385-0 · Cited by 5
Nintedanib-Induced Colitis Treated Effectively With Budesonide
Amini, A., Koury, E., & Chahla, E. J. (2020) · Cureus · doi:10.7759/cureus.9489 · Cited by 7
“Diarrhea led to permanent dose reduction in 11% of patients and discontinuation in 5% [4].”
BackgroundMethodInfluentialMin, H. K., Kim, S., Lee, S., & Kim, H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.443 · Cited by 5
Imakura, T., Toyoda, Y., Sato, S., et al. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.358 · Cited by 5
Martusewicz-Boros, M. M., & Górska, K. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0190 · Cited by 7
Sumi, T., Uehara, H., Tada, M., Keira, Y., Kamada, K., Shijubou, N., Yamada, Y., Nakata, H., Mori, Y., & Chiba, H. (2021) · Respirology Case Reports · doi:10.1002/rcr2.716 · Cited by 4
Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary Fibrosis Lung Disease
Warrior, K., Chung, P. A., Reid, M., & Bemiss, B. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202012-4356rr · Cited by 5
Chen, C.-Y., Chen, C., Wang, C., Lai, C., Chao, C., & Wei, Y. (2021) · Respiratory Research · doi:10.1186/s12931-021-01839-0 · Cited by 5
Boleto, G., Avouac, J., & Allanore, Y. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211066686 · Cited by 6
Yamakawa, H., Tsukahara, Y., Sato, S., Ohta, H., Kida, G., Nakamura, T., Nishizawa, T., Kawabe, R., Oba, T., Akasaka, K., et al. (2022) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i4.11465 · Cited by 5
Aragona, C. O., Versace, A. G., Ioppolo, C., Rosa, D. L., Lauro, R., Tringali, M. C., Tomeo, S., Ferlazzo, G., Roberts, W. N., Bitto, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020504 · Cited by 6
Dhooria, S., Babu, V., Dhir, V., Sehgal, I. S., Prasad, K. T., Muthu, V., Bal, A., Debi, U., Garg, M. K., Agarwal, R., et al. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.08.004 · Cited by 5
Mlakar, L., Garrett, S. M., Watanabe, T., Sanderson, M., Nishimoto, T., Heywood, J., Helke, K. L., Pilewski, J. M., Herzog, E. L., & Feghali‐Bostwick, C. A. (2022) · Biomedicines · doi:10.3390/biomedicines10112861 · Cited by 6
“Therefore, END55 was tested in fibrotic human lung cores derived from patients with IPF and SSc who underwent lung transplantation.”
BackgroundInfluentialCocconcelli, E., Bernardinello, N., Giraudo, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415890 · Cited by 5
“Pirfenidone and nintedanib are approved for treatment of IPF worldwide, based on their ability to slow down functional decline and disease progression with an acceptable safety and tolerability profile [24,25].”
Background“Hit” to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors
Stylianaki, E.-A., Magkrioti, C., Ladopoulou, E. M., Papavasileiou, K. D., Lagarias, P. I., Melagraki, G., Samiotaki, M. K., Panayotou, G., Dedos, S., Afantitis, A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115130 · Cited by 6
Imaging of pulmonary fibrosis in children: A review, with proposed diagnostic criteria
DeBoer, E. M., Weinman, J. P., Ley‐Zaporozhan, J., Griese, M., Deterding, R. R., Lynch, D. A., Humphries, S. M., & Jacob, J. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26857 · Cited by 9
Mortality in interstitial lung disease: do race and skin colour matter?
Morisset, J., Mageto, Y. N., & Raghu, G. (2018) · European Respiratory Journal · doi:10.1183/13993003.00892-2018 · Cited by 5
Self-citationRemission of psoriasis with nintedanib for the treatment of idiopathic pulmonary fibrosis
Murata, A., Watanabe, S., Ikawa, Y., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14641 · Cited by 5
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 123
Nathan, S. D. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1510ed · Cited by 5
Chen, L., Halai, V., Leandru, A., & Wallis, A. (2019) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000915 · Cited by 6
Majewski, S., Lewandowska, K. B., Martusewicz-Boros, M. M., & Piotrowski, W. J. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2019.0060 · Cited by 6
The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
Moor, C. C., Kreuter, M., Luppi, F., & Wuyts, W. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-01377-1 · Cited by 7
“Nevertheless, it should be noted that these clinical trials included a selected subgroup of patients with IPF, with relatively few comorbidities, strict lung function criteria, and age restrictions [4, 5, 17].”
BackgroundLi, Y., Wu, G., Shang, Y., Qi, Y., Wang, X., Ning, S., & Chen, H. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01350-0 · Cited by 7
“Currently, several studies have confirmed that nintedanib (an intracellular inhibitor for multiple target genes, including VEGF, FGF, PDGF receptors and so on) is beneficial for patients with IPF [19 – 21].”
BackgroundCurrent therapy of interstitial pneumonia associated with systemic scleroderma
Ananieva, L. (2020) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-520-531 · Cited by 6
New guideline on treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Bonella, F., & Maher, T. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00322-7 · Cited by 5
Die idiopathische Lungenfibrose
Prasse, A. (2015) · Pneumologie · doi:10.1055/s-0034-1393036 · Cited by 5
MicroRNAs in Idiopathic Pulmonary Fibrosis
Pandit, K. V., & Kaminski, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800553-8.00007-x · Cited by 5
Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration
Abdi, B. A., Lopez, H., Karrar, S., Renzoni, E. A., Wells, A. U., Tam, A. Y. Y., Etomi, O. T., Hsuan, J. J., Martin, G. R., Shiwen, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02621-3 · Cited by 5
Okamori, S., Asakura, T., Masuzawa, K., Yasuda, H., Kamata, H., Ishii, M., & Betsuyaku, T. (2017) · Medicine · doi:10.1097/md.0000000000009081 · Cited by 5
Familial pulmonary fibrosis: a world without frontiers
Borie, R., & Crestani, B. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20190303 · Cited by 6
“That has led to the development of well-accepted diagnostic criteria for idiopathic pulmonary fibrosis (IPF),(1,2) as well as to the development of two drugs, pirfenidone and nintedanib,(3,4) which are able to slow the progression of the disease and may improve survival.”
Background
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.